Compare ASE Technology Holding Co Ltd (ASX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Cassava Sciences Inc — how do they compare? ASE Technology Holding Co Ltd trades at $39 (market cap $85.75B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: ASE Technology Holding Co Ltd is far larger — about 1795.8× Cassava Sciences Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.08% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ASX | FLNA | |
|---|---|---|
Market Cap | $85.75B | $47.75M |
Sector | Technology | Health |
52-Week High | $45.12 | $4.64 |
52-Week Low | $9.63 | $0.87 |
Enterprise Value | $90.15B | -$34.93M |
Dividend Yield | 1.08% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
